We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.93B
AUM Growth
-$733M
Cap. Flow
-$52.9M
Cap. Flow %
-1.07%
Top 10 Hldgs %
45.48%
Holding
165
New
19
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
OTLY
Oatly Group
OTLY
+$37.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$32.5M
3
TRML
Tourmaline Bio
TRML
+$31.6M
4
SAGE
Sage Therapeutics
SAGE
+$24.7M
5
VERV
Verve Therapeutics
VERV
+$20.8M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$98.3M
2
INTC icon
Intel
INTC
+$47M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$38.4M
4
AVGO icon
Broadcom
AVGO
+$34.8M
5
BEKE icon
KE Holdings
BEKE
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75.69%
2 Consumer Discretionary 10.87%
3 Miscellaneous 10.83%
4 Consumer Staples 0.74%
5 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
126
DELISTED
Avidity Biosciences
RNAM
$3.52M 0.07%
142,500
– –
MTCR
127
DELISTED
Metacrine, Inc. Common Stock
MTCR
$3.52M 0.07%
924,898
– –
PARA
128
DELISTED
Paramount Global Class B
PARA
$3.39M 0.07%
75,000
+7,500
+11% +$310K
SGTX
129
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$2.96M 0.06%
21,231
– –
KNTE
130
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.91M 0.06%
125,000
– –
AXLA
131
DELISTED
Axcella Health Inc. Common Stock
AXLA
$2.86M 0.06%
28,500
– –
LITS
132
Lite Strategy Inc
LITS
$37.1M
$2.85M 0.06%
50,000
+12,000
+32% +$771K
CGEM icon
133
Cullinan Oncology
CGEM
$1.29B
$2.58M 0.05%
100,000
– –
KDNY
134
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.55M 0.05%
180,500
– –
KA
135
DELISTED
Kineta, Inc. Common Stock
KA
$2.53M 0.05%
31,056
– –
LVTX
136
DELISTED
LAVA Therapeutics
LVTX
$2.18M 0.04%
200,000
– –
MOLN
137
Molecular Partners
MOLN
$153M
$2.05M 0.04%
+100,000
New +$1.98M
CHMA
138
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.8M 0.04%
380,000
– –
IRWD icon
139
Ironwood Pharmaceuticals
IRWD
$671M
$1.42M 0.03%
110,532
– –
RIGL icon
140
Rigel Pharmaceuticals
RIGL
$850M
$1.39M 0.03%
32,110
– –
CEREW
141
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$1.15M 0.02%
79,600
– –
SURF
142
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$746K 0.02%
100,000
– –
LU icon
143
Lufax Holding
LU
$1.07B
$565K 0.01%
+12,500
New +$630K
CDTX
144
DELISTED
Cidara Therapeutics
CDTX
$454K 0.01%
11,234
– –
AA icon
145
CALL
Alcoa
AA
$12.3B
– –
-1,500,000
Closed -$48.7M
AVGO icon
146
Broadcom
AVGO
$1.63T
– –
-750,000
Closed -$34.8M
BAC icon
147
CALL
Bank of America
BAC
$414B
– –
-2,000,000
Closed -$77.4M
BEKE icon
148
KE Holdings
BEKE
$17.8B
– –
-600,000
Closed -$34.2M
BMRN icon
149
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-150,000
Closed -$11.3M
BNTX icon
150
BioNTech
BNTX
$24.2B
– –
-900,000
Closed -$98.3M
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2021 Portfolio in Review

As of Q2 2021, Artal Group held 165 positions worth $4.93B, down 13% from $5.66B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group's Q2 2021 filing shows 19 new, 18 increased, 16 reduced and 21 closed positions. Its largest new stake was Oatly Group: 75,000 shares worth $36.7M. The largest sale was BioNTech, an estimated $98.3M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q2 2021 buy was Oatly Group: 75,000 shares worth $36.7M.
  • Artal Group added most to Sage Therapeutics in Q2 2021, an estimated $24.7M increase.
  • Artal Group's biggest Q2 2021 reduction was TG Therapeutics, cutting an estimated $27.5M.
  • Artal Group fully exited BioNTech in Q2 2021, selling an estimated $98.3M.
  • Artal Group's ten largest holdings make up 45% of its $4.93B portfolio in Q2 2021.
  • Artal Group opened 19 new positions and closed 21 in Q2 2021.
  • Artal Group's portfolio value fell 13% quarter-over-quarter to $4.93B.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.